Who is sponsoring ATTRACT?

ATTRACT is sponsored by Washington University School of Medicine.

What condition does ATTRACT study?

ATTRACT studies Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome.

What drugs are being tested in ATTRACT?

Interventions: Recombinant tissue plasminogen activator (rt-PA).

What is the status of ATTRACT?

ATTRACT is currently COMPLETED.

Last reviewed 2018-02-28 · How we verify

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial

NCT00790335 Phase 3 COMPLETED Results posted

The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.

Details

Lead sponsor	Washington University School of Medicine
Phase	Phase 3
Status	COMPLETED
Enrolment	692
Start date	2009-11
Completion	2017-01

Conditions

Deep Vein Thrombosis
Venous Thrombosis
Postphlebitic Syndrome
Venous Thromboembolism
Post Thrombotic Syndrome

Interventions

Recombinant tissue plasminogen activator (rt-PA)

Primary outcomes

Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — Between 6 and 24 months after randomization
Patients who experienced one of the following occurrences in the index leg between the 6 month and 24 month post-randomization follow-up visits, inclusive: 1) Villalta score of 5 or greater; 2) leg ulcer; or 3) late endovascular procedure performed to treat severe venous disease. The Villalta scale ranges from 0-33 points, with higher scores being worse.

Countries

United States